> Detailanzeige

Brookshire, Heather L.; English, Robert V.; Nadelstein, Bradley; Weigt, Anne K.; Gift, Barrett W.; Gilger, Brian C.

Efficacy ofCOX‐2 inhibitors in controlling inflammation and capsular opacification after phacoemulsification cataract removal

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Efficacy ofCOX‐2 inhibitors in controlling inflammation and capsular opacification after phacoemulsification cataract removal
  • Beteiligte: Brookshire, Heather L.; English, Robert V.; Nadelstein, Bradley; Weigt, Anne K.; Gift, Barrett W.; Gilger, Brian C.
  • Erschienen: Wiley, 2015
  • Erschienen in: Veterinary Ophthalmology, 18 (2015) 3, Seite 175-185
  • Sprache: Englisch
  • DOI: 10.1111/vop.12159
  • ISSN: 1463-5216; 1463-5224
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: AbstractObjectiveTo evaluate the efficacy of 0.9% bromfenac (Xibrom™) or a celecoxib‐impregnated intraocular lens (celecoxib‐IOL) compared with 1% prednisolone acetate (PA) in controlling postoperative inflammation and posterior capsule opacification (PCO).Animal studiedFifty‐nine dogs undergoing cataract extraction by phacoemulsification.ProcedureBilateral patients received bromfenac or celecoxib‐IOLplusPAin one eye, andPAin the contralateral eye. Unilateral patients received bromfenac orPA. Complete ophthalmic examination including tonometry, slit‐lamp grading of flare andPCO, and digital image acquisition for maskedPCOevaluation was performed within 24 h and 1, 4, 12, 24, and 56 weeks following surgery.ResultsCelecoxib‐IOL/PA‐treated eyes had significantly less flare thanPA‐treated eyes, which had significantly less flare than bromfenac‐treated eyes 24 h postoperatively. There was no significant difference in intraocular pressure (IOP) postoperatively, or at 1, 24, or 56 weeks. Celecoxib‐IOL/PA‐treated eyes had significantly lowerIOPmeasurements than bromfenac andPA‐treated eyes at 4 and 12 weeks. There was no significant difference inPCOlevel between groups using slit‐lamp biomicroscopy at any time point. Masked evaluation of digital images revealed significantly lessPCOin celecoxib‐IOL/PA‐ vs. bromfenac‐treated eyes at 4 weeks, and in bromfenac‐ vs.PA‐treated eyes at 56 weeks.ConclusionsEyes receiving celecoxib‐IOL/PAhad better initial control of inflammation. Bromfenac was equally effective compared withPAin controlling inflammation. There was no association betweenCOX‐2 inhibitor administration and ocular hypertension. Celecoxib‐IOL/PA‐treated eyes showed better initial control ofPCO(up to 12 weeks), while eyes receiving bromfenac had better long‐term control ofPCO(56 weeks).